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Background: Many options are available for preventing people from getting infected
by influenza virus, with vaccination being the most widely used.
Methods: We assessed the evidence available in Cochrane systematic reviews. We
found nine reviews, five of them addressing influenza vaccination, and four
addressing medication.
Results: Vaccination is effective in healthy adults and children, but the effect is
modest in adults, and for young children few data are available. In patients with
asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, more
evidence is needed to determine effectiveness. Vaccination does not result in
exacerbation of asthma. Neuraminidase inhibitors may also have a place in limiting
the spread of infection, at least in adults. Amantadine and rimantadine seem
effective but have unfavourable adverse-effect profiles. The popularity of
homoeopathic Oscillococcinum, especially in France, is not supported by current
evidence.
Conclusion: In many areas, more clinical trials are needed, as the current evidence
is inconclusive. Furthermore, several other measures that may be helpful in
preventing influenza that have not been addressed in Cochrane reviews.
& 2005 Published by Elsevier Ltd.Published by Elsevier Ltd.
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Influenza is a disease of viral origin that occurs
worldwide, usually in seasonal epidemics. The
annual incidence varies from year to year and from
region to region. In a typical epidemic season,
about 5–15% of adults and children develop
symptomatic influenza.1 To reduce the substantial
morbidity and mortality one requires the use of
preventive strategies that have proved to be
effective.
Several potential strategies can prevent people
from getting infected by influenza virus or, once
infected, developing illness. Examples are hygienic
measures, antiviral medication and vaccination.
Vaccination is considered to be the principal
measure for preventing influenza and reducing
the affect of epidemics. World wide, immunization
programmes have been implemented, particularly
aimed at elderly people and people with specific
chronic disorders. However, the uptake rate varies
substantially,2,3 and, recently, there have been
supply chain problems.4
In this paper, we review the available evidence
on measures for preventing influenza. We will
restrict ourselves to interventions that have been
the subject of Cochrane systematic reviews, as
these reviews may be considered at the top of the
hierarchy of levels of evidence, being restricted to
randomized-controlled trials (RCTs) and performed
in the most systematic way according to predefined
protocols.Methods
In November 2004, we searched the Cochrane
Library for relevant reviews, using ‘‘influenza’’ as
a search term. The full text of each of the reviews
resulting from this search was screened to verify
that the intervention studied, was aimed at
preventing influenza.Results
The search provided 80 completed Cochrane
systematic reviews in which the term ‘‘influenza’’
appeared. Eight of these focused on preventing
influenza: four of these addressed the effect of
vaccination and four the effect of medications, one
of them homeopathic. A review addressing influen-
za vaccination in healthy children, using Cochrane
methodology, published in The Lancet in February
2005, was also included.5 Reviews were excluded ifthey did not address interventions for influenza,
but were found by the search strategy because the
word ‘‘influenza’’ was mentioned for other reasons.
A brief summary of the findings of all reviews is
given in Table 1. For each selected review, we will
provide details of methods and results. Some of the
reviews addressed both the prevention of influenza
and reduction of illness when infected with
influenza. We will not describe the results relating
to the reduction of illness, as this is beyond the
scope of this paper.
Methods common to all reviews
All the included Cochrane reviews were conducted
after searching the literature in various databases,
notably the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE and EMBASE. Some
reviews also used specialized databases within the
Cochrane Collaboration, such as the Cochrane
Airways Group trial register. The date of the most
recent search varied between reviews, and is
specified in the results of the review. In addition
to searching these databases, the authors of the
reviews also checked references of relevant arti-
cles, wrote to manufacturers of drugs and vaccines,
and to authors of studies to ask for additional
studies, published or unpublished.
For most of the reviews, extraction of data and
assessment of methodological quality were carried
out by more than one reviewer independently.
Cochrane review on influenza vaccine in
healthy adults
Traditionally, influenza vaccination programmes
have targeted elderly people and those at serious
risk of complications. Healthy adults may also
benefit from vaccination, as influenza may result
in loss of working days, and affected employees
may spread the disease to others. The authors set
out to identify studies that assessed the effective-
ness of vaccines in preventing cases of influenza in
healthy adults, as well as their adverse effects.6
The last search of the literature for this Cochrane
review was carried out in 2003. The authors
included any randomized or quasi-randomized
studies comparing influenza vaccines in humans
with placebo, control vaccines or no intervention,
or comparing types, doses or schedules of influenza
vaccine. All routes of administration of vaccines
(i.e. intramuscular, subcutaneous, intranasal) were
considered. Only studies assessing protection by
vaccination from exposure to naturally occurring
influenza in healthy individuals aged 14–60 years
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Table 1 Summary of Cochrane systematic reviews on preventing influenza.
Topic of Cochrane review Most recent
search
Number of
studies included
Authors’ conclusion
Influenza vaccine in healthy
adults6
2003 25 RCTs Effective in reducing
serologically confirmed cases.
Less effective in reducing cases
of clinical influenza or working
days lost.
Influenza vaccine in healthy
children5
2004 25 (15 RCTs) Effective in reducing laboratory
confirmed influenza in children
older than 2 years of age. Less
effective in reducing influenza-
like illness or influenza
complications.
Influenza vaccine in patients
with asthma7
2004 14 RCTs No significant increase in
asthma exacerbations after
vaccination.
Uncertainty about degree of
protection by vaccination.
Influenza vaccine in patients
with chronic obstructive
pulmonary disease9
2001 9 RCTs Inactivated vaccine may reduce
exacerbations.
Influenza vaccine in cystic
fibrosis patients12
2001 4 RCTs No evidence.
Amantadine and rimantadine in
adults13
2003 30 RCTs Amantadine significantly
prevents influenza-like illness
and influenza A. For
rimantadine, no significant
reduction was found. Both drugs
induce significant adverse
effects.
Neuraminidase inhibitors in healthy
adults14
1999 4 RCTs Effective in preventing
influenza. Overall, they are
safe, although oseltamivir
causes significant
nausea.
Neuraminidase inhibitors in
children15
2002 3 RCTs Ability to prevent influenza
infection in children remains
unproven.
Homeopathic Oscillococcinum16 2003 7 RCTs No support for a preventive
effect.
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considered.
Twenty-five reports of studies involving 59,566
people were included. Live aerosol vaccines re-
duced the number of cases of serologically con-
firmed influenza by 48% (95% confidence interval
[CI] 24–64%), whereas inactivated parenteral vac-
cines had a much larger efficacy, reducing the
number of serologically proven cases by 70% (95% CI
56–80%). The vaccines had low effectiveness
against clinical influenza cases: 15% reduction
(95% CI 8–21%) and 25% reduction of clinical cases
compared with placebo (95% CI 13–35%), respec-tively. Overall, the percentage of participants
experiencing clinical influenza decreased by 7%
(20% vs. 13%: number needed to treat is 14). Use of
the vaccine significantly reduced time off work, but
only by 0.16 days for each influenza episode (95% CI
0.04–0.29 days).
The authors of this review conclude that influ-
enza vaccines are effective in reducing serologi-
cally confirmed cases of influenza. However, they
are not as effective in reducing cases of clinical
influenza and number of working days lost. One of
the reasons is that not all influenza infections that
can be detected serologically result in clinical
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tion of healthy adults is not supported by the
results of their review.Cochrane review on influenza vaccine in
healthy children
Schoolchildren were the focus of influenza vaccina-
tion in Japan in the second half of last century, and
recently the American Academy of Pediatrics has
recommended vaccination of children aged 6–23
months. Various reasons have been put forward to
underpin these recommendations but, until re-
cently, thorough assessment of the benefit of
vaccinating children was absent.
In their review, part of a forthcoming larger
Cochrane review, the authors set out to identify
studies that assessed the effectiveness of influenza
vaccines in preventing cases of influenza, as well as
several other related outcomes in healthy children
up to 16 years of age.5
The last search of the literature for this Cochrane
review was carried out in 2004. The authors
included randomized, cohort and case-control
studies comparing efficacy of vaccines against
influenza (reduction in laboratory-confirmed
cases), effectiveness against influenza-like illness
(reduction in symptomatic cases), or both, with
placebo or no intervention. The authors analyzed
the following outcomes: influenza confirmed by
viral isolation, serological support or any other type
of laboratory testing; influenza-like illness; admis-
sions for influenza or influenza-like illness; death
due to influenza or influenza-like illness. Serologi-
cal outcome data were not considered.
Twenty-five reports of studies were selected,
reporting on 15 randomized trials, eight cohort
studies and one case-control study. We will focus on
the results that were provided by the randomized
trials. Live attenuated vaccines reduced the num-
ber of cases of laboratory-confirmed influenza by
79% (95% CI 48–92%). No data were available for
children below the age of 3 years. Inactivated
vaccines reduced the number of cases by 65% (95%
CI 47–76%). In children aged 6 years or younger, the
reduction was much smaller and did not reach
statistical significance. Both types of vaccines had
lower effectiveness against influenza-like illness:
38% reduction (95% CI 33–43%) and 28% reduction of
cases compared with placebo or no intervention
(95% CI 22–33%) for live attenuated and inactivated
vaccine, respectively. Overall, the percentage of
participants experiencing clinical influenza de-
creased by 15% (17% vs. 2%: number needed to
treat is about 7) in the case of live attenuatedvaccine and 19% (26% vs. 7%: number needed to
treat is about 5) in the case of inactivated vaccine.
Few studies provided data on other influenza-
related outcomes. Vaccines were somewhat effec-
tive in reducing school absence, but they had little
effect on other outcomes (secondary cases, lower-
respiratory tract disease, acute otitis media,
hospital stay), compared with placebo. Death due
to influenza or to influenza-like illness was not
reported.
The authors conclude that influenza vaccines do
reduce influenza infection in children older than 2
years. The reduction of influenza-like illness is
much lower. The authors state that if influenza
immunization in children is to be recommended as
public-health policy, large-scale studies are ur-
gently needed that address important outcomes
such as mortality, serious complications and com-
munity transmission of influenza.Cochrane review on influenza vaccine in
people with asthma
Influenza vaccination is recommended for asth-
matic patients in most Western countries, as
influenza infection may trigger asthma exacerba-
tions. However, this is controversial as vaccination
may precipitate an asthma attack. The objective of
this review was to assess the efficacy and side-
effects of influenza vaccination in children and
adults with asthma.7
The last search of the literature was carried out
in 2004. The authors selected randomized trials of
influenza vaccination in children (over 2 years of
age) and adults with asthma. Studies involving
people with chronic obstructive pulmonary disease
(COPD) were excluded.
Fourteen trials were included. The included
studies covered a wide diversity of populations,
settings and types of influenza vaccination. Data
from the more recent studies that used similar
vaccines were pooled. The pooled results of two
trials involving 2306 people with asthma did not
demonstrate any increase in asthma exacerbations
in the 2 weeks after influenza vaccination (risk
difference 0.00; 95% CI 0.02 to 0.02). A recent
study of 696 children with asthma did not demon-
strate a significant reduction in influenza-related
asthma exacerbations (risk difference 0.01; 95% CI
0.02 to 0.04).8
The authors conclude that there is no significant
increase in asthma exacerbations immediately
after vaccination (at least with inactivated influ-
enza vaccination); however, uncertainty remains
about the degree of protection vaccination affords
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influenza infection.Cochrane review on influenza vaccine in
people with chronic obstructive pulmonary
disease
Influenza vaccinations are currently recommended
in the care of people with COPD in many countries,
but these recommendations are based largely on
evidence from observational studies. Influenza
infection causes excess morbidity and mortality in
patients; however, in this group, influenza vaccina-
tion may cause adverse effects. Moreover, its cost-
effectiveness has to be established in this group.
The objective of this review was to evaluate the
evidence from RCTs for a treatment effect of
influenza vaccination in people with COPD.9 Outcomes
of interest were exacerbation rates, hospitalizations,
mortality, lung function and adverse effects.
The last substantive update to this review was
made in 2000. The review included RCTs that
compared live or inactivated virus vaccines with
placebo, either alone or combined with another
vaccine, in people with COPD. Studies of people
with asthma were excluded.
Nine trials were included, but only four of these
were specifically carried out in people with COPD.
The others were conducted on elderly and high-risk
individuals, some of whom had COPD. In one study
of inactivated influenza vaccine in people with
COPD, there was a significant reduction in the total
number of exacerbations per vaccinated individual
compared with those who received placebo
(weighted mean difference [WMD] 0.45, 95% CI
0.75 to 0.15). This difference was mainly due to
the reduction in number of exacerbations occurring
in the period beyond 3 weeks after administration
(WMD 0.44; 95% CI 0.68 to 0.20). The number
of patients experiencing exacerbations in this
period was also significantly less (OR ¼ 0.13, 95%
CI 0.04–0.45). There was no evidence of an effect
of intranasal live attenuated virus when this was
added to inactivated intramuscular vaccination. In
studies of elderly patients (only a minority of whom
had COPD), there was a significant increase in the
occurrence of local adverse reactions in vaccinees,
but the effects were generally mild and transient.
The authors conclude that, on the basis of a
limited number of RCTs, inactivated vaccine may
reduce exacerbations in people with COPD. In
elderly, high-risk people, vaccination caused an
increase in adverse effects, but these were seen
early and were usually mild and transient.This review is in the process of being updated, as
there have been recent publications resulting from
the findings of a large RCT carried out in Thailand
that included a cost-effectiveness analysis.10,11
Cochrane review on influenza vaccine in
people with cystic fibrosis
Viral respiratory-tract infections in patients with
cystic fibrosis have a detrimental effect on lung
function and disease progression. Annual influenza
vaccination is, therefore, recommended for patients
with cystic fibrosis. The objective of this review was
to assess the effectiveness and adverse events of
influenza vaccination for people with cystic fibrosis.12
The date of the most recent search of the
literature was November 2001. The authors in-
cluded all randomized and pseudo-randomized
trials (published or unpublished) comparing any
influenza vaccine with a placebo or with another
type of influenza vaccine.
Four trials enrolling a total of 179 patients with
cystic fibrosis (80% of which were children aged 1–16
years) were included in this review. No studies were
found comparing a vaccine to a placebo, or a whole
virus vaccine to a subunit or split virus vaccine. Two
studies compared an intranasal applied live vaccine
to an intramuscular inactivated vaccine, and the
other two studies compared a split virus with a sub-
unit vaccine, and a virosome to a sub-unit vaccine
(all intramuscular). The total adverse event rate
ranged from 48 out of 201 (24%) for the intranasal
live vaccine to 13 out of 30 (43%) for the split-virus
vaccine. No severe adverse events were reported.
With the limitation of low statistical power, there
was no significant difference in the occurrence of
adverse events between the vaccines used. All
studied vaccines generated a satisfactory serological
antibody response, but other clinically more im-
portant benefits were not found.
The conclusion of the review is that there is
currently no evidence from randomized studies
that influenza vaccine benefits people with cystic
fibrosis. There remains a need for a well-con-
structed clinical study that assesses the effective-
ness of influenza vaccination on important clinical
outcome measures, such as subsequent pseudomo-
nas infection, lung function, length of hospital stay
and nutritional status.
Cochrane review on amantadine and
rimantadine in adults
Amantadine hydrochloride and rimantadine hydro-
chloride have antiviral properties, but these drugs
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their potential value and concerns about possible
adverse effects. The objective of this review was to
assess the effectiveness and safety of amantadine
and rimantadine in healthy adults.13
The last search of the literature was conducted
in 2003. The authors included 30 randomized and
quasi-randomized studies comparing amantadine,
rimantadine, or both, with placebo, control anti-
virals or no intervention, or comparing doses or
schedules of amantadine, rimantadine, or both, in
healthy adults. For prevention trials, the numbers
of participants with influenza-like-illness or con-
firmed influenza A, and adverse effects were
analysed.
Amantadine prevented 25% of cases of influenza-
like illness (95% CI 13–36%), and 61% of influenza A
cases (flu symptoms combined with laboratory
findings) (95% CI 35–76%). For rimantadine, the
results for prevention were not statistically sig-
nificant. Both amantadine and rimantadine induced
significant gastrointestinal adverse effects. Adverse
effects of the central nervous system and study
withdrawals were significantly more common with
amantadine than with rimantadine.Cochrane review on neuraminidase
inhibitors in healthy adults
In the 1990s, neuraminidase inhibitors became
available for the prevention and treatment of
influenza. Neuraminidase inhibitors act by inhibit-
ing the entry of viral particles into the target and
subsequent release of virions from the infected
cell, neuraminidase being essential for both func-
tions. Neuraminidase inhibitors are available as a
metered dose aerosol (zanamivir) or as oral
suspension (oseltamivir).
One of the objectives of this review was to assess
the effects of neuraminidase inhibitors in prevent-
ing cases of influenza.14 A further objective was to
estimate the frequency of adverse effects asso-
ciated with neuraminidase inhibitor administration.
The last search of the literature was carried out in
1999. The authors included randomized or quasi-
randomized placebo-controlled studies of neurami-
nidase inhibitors in healthy adults.
Studies assessing protection from exposure to
naturally occurring and experimental influenza
(challenge studies) were considered. The main
outcomes were numbers, severity, or both, of
influenza cases and the number and seriousness of
adverse effects.
Four preventive trials were found. The manufac-
turers provided additional data. The methodologi-cal quality of the studies was difficult to assess,
owing to a lack of detailed descriptions. Compared
with placebo, neuraminidase inhibitors were 74%
effective (95% CI 50–87%) in preventing naturally
occurring cases of clinically defined influenza, and
60% effective (95% CI 76–33%) in preventing cases of
laboratory-confirmed influenza.
Adverse events, especially local nasal irritation,
in the group treated with zanamivir, did not differ
from that of placebo; odds ratio 1.19 (95% CI
0.39–3.62). Compared with rimantadine as a pre-
ventive measure, oseltamivir showed a significantly
lower incidence of adverse effects and a signifi-
cantly higher incidence of nausea.
The reviewers conclude that neuraminidase
inhibitors are effective for the prevention of
influenza. Overall, neuraminidase inhibitors are
safe, although oseltamivir causes significant
nausea.Cochrane review on neuraminidase
inhibitors in children
General information on neuraminidase inhibitors
and their role in influenza prevention was provided
in the previous section. The objective of this
review was to assess the efficacy, safety and
tolerability of neuraminidase inhibitors in the
treatment and prophylaxis of influenza infection
in children.15
The last search of the literature was carried
out in 2002. The authors included double-blind,
RCTs comparing neuraminidase inhibitors with
placebo or other antiviral drugs in children less
than 12 years of age. Additional safety and
tolerability data from other sources were also
included. Data were analysed separately for osel-
tamivir and zanamivir.
The authors identified three trials of neuramini-
dase inhibitors in the prevention of influenza in
families (including children). However, the compa-
nies that performed these trials were not willing to
separate out the data for paediatric populations,
and so no data from these studies were eligible for
inclusion in the review.
The adverse-events profile of zanamivir was no
worse than placebo and no reports of zanamivir-
induced bronchospasm in children were found.
Vomiting was more common in children treated
with oseltamivir than in children treated with
placebo (14.8 vs. 9.3%).
The authors conclude that the ability of neur-
aminidase inhibitors to prevent influenza infection
in children remains unproven.
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Oscillococcinum is a patented, commercially avail-
able homoeopathic medicine. The medicine is
manufactured from wild duck heart and liver,
which are said to be reservoirs for influenza viruses.
Scarcely known in the English-speaking world, it is
one of the most widely used and popular homeo-
pathic medicines in France, introduced in the
1930s.
The authors’ objective was to determine
whether homoeopathic Oscillococcinum or similar
medicines are more effective than placebo in the
prevention and treatment of influenza and influen-
za-like syndromes.16 Here, we will focus on
prevention.
The last search of the literature was done in
2003. The authors included placebo-controlled
trials of Oscillococcinum or homoeopathically pre-
pared influenza virus, influenza vaccine or avian
liver in the prevention and treatment of influenza
and influenza-like syndromes.
Of the seven studies that were included in this
review, three addressed the prevention of influen-
za, with a total number of 2265 patients. Two of the
prevention trials used prepared–prepared mixtures
of inactivated bacteria and influenza viruses.
The third used extract of heart and liver of wild
duck (similar to that used in the preparation of
Oscillococcinum) in a 200C potency (i.e. diluted 1
in 100 repeated 200 times). There was no evidence
that homoeopathic treatment can prevent influen-
za-like syndrome (relative risk 0.64, 95% CI
0.28–1.43).
The authors conclude that current evidence does
not support a preventive effect of Oscillococcinum-
like homeopathic medicines in preventing influenza
and influenza-like syndromes.Discussion
We found nine Cochrane reviews that specifically
focused on the prevention of influenza, five of
which addressed vaccination and four medication.
For six reviews, the most recent search of the
literature was carried out in 2002–2004. However,
the other three reviews have not been updated for
several years,9,12,14 although this may be due to a
lack of new studies. However, the findings for
interventions that have become recently available
and are widely advised, such as the neuraminidase
inhibitors,12,14 should be interpreted with caution,
as there may be more recent trials that provide
evidence to alter the original review’s conclusions.With one exception, all reviews were restricted
to controlled trials, although the strictness relating
to randomization differed. The review on influenza
vaccination in healthy children also included cohort
studies and case-control studies, but, for this
overview, we only used results from the rando-
mized trials. Some of the reviews allowed pseudo-
or quasi-randomization. Similarly, some authors
required all studies to be double-blind, whereas
others also allowed single-blind studies. In any
case, by restricting reviews to controlled trials with
some sort of randomization and blinding, it is likely
that the best available evidence has been gath-
ered. As the number of studies will increase in the
future, restriction to studies of high methodologi-
cal quality should be considered.
Other strategies that may be helpful in prevent-
ing influenza, but are not yet subjects of Cochrane
reviews, include restricting circulation of viruses
(e.g. by increasing vaccination rates or by vacci-
nating all children,17 vaccinating pregnant wo-
men,18 promoting hand washing,19,20 not blowing
nose,21 and taking measures in poultry farms22).
Other therapies, such as vitamin C and Echina-
cea, have been reviewed for their effects on
preventing the common cold. As it is often difficult
to distinguish episodes of influenza illness from
illness due to other viruses, it cannot be ruled out
that some of these therapies also have a role in
preventing influenza. However, as the reviews on
the common cold did not look at the causative
agents, no data are available on the role of these
therapies in preventing influenza.
Influenza vaccination is currently recommended
for use in patients with a variety of conditions,
including cardiovascular disease, respiratory ill-
ness, diabetes, renal disease, immunodeficiencies,
children on long-term aspirin, children under the
age of 2 years and pregnant women. Other target
groups are nursing-home residents, health-care
personnel and household contacts of influenza
patients.23 It is clear that the evidence for
effectiveness in many of these groups has not yet
been covered by individual Cochrane systematic
reviews. The most likely reason is that few RCTs
have been conducted in these groups. The partici-
pants in these groups are often subsets of larger
groups (e.g. elderly people). Trials may be old,
limiting any ability to obtain data for meta-analysis
from the authors. In future RCTs, it may be
unethical to conduct a placebo-controlled RCT of
influenza vaccine in chronically ill elderly people,
where guidelines recommend it universally, as for
example in COPD.24–26
Several of the identified gaps may be filled by
reviews that will be completed in the near future.
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development of reviews for influenza vaccination in
elderly people and in people with HIV/AIDS;
influenza vaccination to prevent myocardial infarc-
tion; amantadine and rimantadine for influenza A in
children and the elderly.
The largest body of evidence to support the
recommendations for influenza vaccination in
chronically ill elderly people comes from observa-
tional studies (e.g. the work of Nichol et al.27,28) A
meta-analysis of 20 cohort studies of influenza
vaccination in elderly people showed a 56% reduc-
tion in respiratory illness, a 53% reduction in
pneumonia, a 50% reduction in hospitalization,
and a 68% reduction in deaths from all causes
during influenza outbreaks.29 A major problem with
observational studies is that it is impossible to rule
out bias. Reasons why people were vaccinated or
were not vaccinated may be related to their health
status, which in turn may be related to the chance
of getting infected.Conclusion
A range of options is available for preventing
influenza, with some having been studied more
extensively than others. Most of the interventions
to prevent influenza have unknown or disappointing
effects. The evidence from RCTs, accumulated in
current Cochrane systematic reviews, supports
vaccinating healthy workers, although the effects
are small. Antivirals, especially zanamivir and
oseltamivir, may also have a place in the prevention
of spreading the virus, although this review has not
been recently updated. In people with chronic
diseases, there is limited evidence in support of
vaccination for people with COPD, but no evidence
yet of effectiveness in asthma or cystic fibrosis. The
reviews do, however, suggest that vaccination is
safe in all these groups.
Practice points
 At the moment, Cochrane systematic re-
views address only some of the options
available for preventing influenza
 Influenza vaccination does not cause ex-
acerbations of chronic respiratory diseases
 There is, as yet, very little RCT evidence of
effectiveness of vaccination in preventing
exacerbations of chronic respiratory disease
 Vaccinating healthy workers and healthy
children is effective, but the effect on the
first is modest Neuraminidase inhibitors, zanamivir and
oseltamivir, may also have a place in limit-
ing the spread of infection, and showed less
adverse effects than older antiviral medica-
tion (amantadine and rimantadine)
 The popularity of homoeopathic Oscillococ-
cinum in some parts of the world is not
supported by current evidenceResearch directions
 Most of the systematic reviews ask for new,
well-designed clinical trials, as the current
evidence is inconclusive
 New Cochrane reviews are needed for
several measures that may be helpful in
preventing influenza. Some of these are at
the protocol stage; however, other reviews
need to be designed and conducted
 Priority should be given to conducting
reviews on the effect of influenza vaccina-
tion in the high-risk groups mentioned in
recommendations worldwideReferences
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